Authors/Disclosures
|
Shnehal Patel, MD
|
Dr. Patel has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Abbvie. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Abbvie. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Adamas. Dr. Patel has received personal compensation in the range of $500-$4,999 for serving on a Speakers Bureau for Neurocrine. |
|
Caroline Goldin, MD
|
Dr. Goldin has nothing to disclose. |
|
Samuel F. DeStefano, MD
(U of Colorado, Neurology)
|
No disclosure on file |
|
Douglas Ney, MD, FAAN
|
The institution of Dr. Ney has received research support from Orbus Therapeutics. The institution of Dr. Ney has received research support from Denovo Biopharma. |
|
Richard L. Hughes, MD, FAAN
(University of Colorado Denver)
|
No disclosure on file |
|
Kenneth L. Tyler, MD, FAAN
(University of Colorado School of Medicine)
|
Dr. Tyler has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Protagonist Therapeutics, Newark CA. Dr. Tyler has received personal compensation in the range of $50,000-$99,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for American Neurological Association/Wiley. Dr. Tyler has received intellectual property interests from a discovery or technology relating to health care. Dr. Tyler has received publishing royalties from a publication relating to health care. Dr. Tyler has a non-compensated relationship as a Director (ex officio) with American Neurological association that is relevant to AAN interests or activities. Dr. Tyler has a non-compensated relationship as a Director with International Society for Neurovirology that is relevant to AAN interests or activities. |
|
Daniel Vela-Duarte, MD
(Palm Beach Neuroscience Institute)
|
Dr. Vela-Duarte has nothing to disclose. |